Corcept's Cushing's candidate continues to impress
This article was originally published in Scrip
Executive Summary
Corcept Therapeutics has released further top-line Phase III data reinforcing the clinical profile of its potential treatment for Cushing's syndrome, Corlux (mifepristone).